Avenacy key facts
as of Oct 2026- Operator of a pharmaceutical firm intended to make critical injectable medications.
- Avenacy is valued at approximately $40.0M as of Oct 2026, set at its early-stage round, Dec 2024; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $26.0M across 1 recorded rounds; the latest was Early Stage VC ($26.0M) in Nov 2024.
- Notable investors include NantWorks.
- Avenacy has filed 1 Form D with the SEC, most recently Nov 2024 ($26.0M sold to 2 investors).
- Status: Privately Held (backing).
Valued at $40.0M at its early-stage round, Dec 2024. Nothing has traded since.
- ·Watch Avenacy: the Monday email on marks, rounds and moves
Avenacy funding rounds
1 roundsWho backs Avenacy
1Avenacy valuation
Avenacy was valued at $40 million at its early-stage round in Dec 2024. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Avenacy raised?
Avenacy has raised $26 million across 1 recorded round since 2024. The largest was a $26 million early-stage round in Nov 2024.
Avenacy has filed 1 Form D with the SEC, most recently in Nov 2024 ($26 million sold to 2 investors).
Avenacy investors
1 investor is on record for Avenacy, including NantWorks. The early-stage round in Nov 2024 drew 2 investors.
About Avenacy
Operator of a pharmaceutical firm intended to make critical injectable medications. The company focuses on developing, manufacturing, and delivering critical medications used to treat patients in various settings, from acute care hospitals to outpatient clinics and physician offices, enabling doctors to treat patients with varying medical conditions.
- Sector
- Healthcare
- HQ
- Schaumburg, IL, United States
- Founded
- 2023
- Employees
- 26
- Website
- avenacy.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.